TriHealth Laboratories REFLEX TESTING

Reflex testing is an important tool in providing timely, cost-effective and quality care to patients. A reflex test is a laboratory test performed (and charged for) subsequent to an initially ordered and resulted test. Reflex testing occurs when an initial test result meets pre-determined criteria (e.g., positive or outside normal parameters), and the primary test result is inconclusive without the reflex or follow-up test. It is performed automatically without the intervention of the ordering physician. Reflex testing may prevent the need for additional specimen procurement from the patient.

The reflex test adds valuable diagnostic information and is consistent with best medical practices. Certain confirmatory reflex tests are required by law; but generally each laboratory establishes its own criteria for medically appropriate reflex tests. A laboratory must disclose to the ordering physician its protocol for performing reflex testing and provide the physician with the opportunity to decline the follow-up tests.

The following chart contains the criteria used for reflex testing at TriHealth Laboratories. Shaded blocks indicate those tests that are performed by a referral laboratory. This information is provided in the Lab User Manual, available on the Bridge for in-house practitioners, and also on the TriHealth Laboratories Test Menu website for outreach clients. Upon major revision, this reflex testing protocol is presented to the Laboratory Utilization and Practice Committee (LUPC) for medical staff approval.

If a physician does not want a reflex test performed according to the protocol established by TriHealth Laboratories, he/she must indicate such at the time the initial test is ordered.

CPT	INITIAL TEST	REFLEX CRITERIA	REFLEX TEST	CPT
85307	Activated Protein C (APC) Resistance	Abnormal ratio or Anticoagulant interference	Factor V Leiden	81241
86038	ANA Screen Reflex to Titer	Positive	Titer	86039
86063	Anti-Streptolysin O (ASO)	Positive	Titer	86060
82175	Arsenic, Urine	35-2000 mcg/L	Fractionated Arsenic, Urine	82175
86615 x3	Bordetella pertussis Antibodies (IgA, IgG, IgM)	IgA ≥1.2 U/mL IgG ≥1.0 U/mL IgM ≥1.2 U/mL	Each Bordetella pertussis Antibody by Immunoblot	86615
85025	CBC Anemia Screening Select pre-op	Hemoglobin <13.0 g/dL Male or <12.0 g/dL Female	Reticulocyte Count B12 Ferritin	85045 82607 82728 83540+83550
	28-week OB Visit	<10.0 g/dL	Iron Battery Differential if WBC <3.6 or >10.5	Replace 85027 with 85025
82784	Celiac Disease Reflexive	IgA <7 mg/dL	tTG IgG and DGP IgG	83516 x2
	Cascade	IgA ≥7 mg/dL but below age-matched	Celiac Dual Antigen Screen with Reflex	83516
		range	If Screen ≥20 Units then tTG IgA and DGP IgA	83516 x2
			If IgA tests negative then tTG IgG and DGP IgG	83516 x2
		Adequate IgA for	tTG IgA	83516
		age	If tTG IgA 4-40 U/mL then DGP	83516
			IgA and EMA IgA by IFA	86256

CPT	INITIAL TEST	REFLEX CRITERIA	REFLEX TEST	CPT
87493	Clostridium difficile PCR	Positive (Infection Prevention specimens do not automatically reflex. Call Infection Prevention Alert.)	Clostridium difficile Toxin A/B	87324
86900 86901 86880	Cord Blood Profile: • ABO Group • Rh Type • Direct Antiglobulin Test (DAT)	Rh Negative DAT Positive	Du Antigen (Weak D) Type and Screen on maternal specimen and/or Antibody Elution on cord blood	86885 86900 86901 86850 86860
86403	Cryptococcal Antigen	Positive	Titer	86406
89051	CSF Cell Count (Emergency Dept. ONLY)	RBC >10/mcL and WBC <10/mcL on CSF Tube #3 or #4	Repeat Cell Count on CSF tube #1	89050
Varies	Culture	Reflex testing depends on specimen and source	Antimicrobial Susceptibility and/or Gram Stain and/or Anaerobic Culture	87186 or 87184 87205 87075
80307	Drug Screen with Reflex to Confirmation	Positive	and/or PCR Panel Confirmation by GC/MS of each component as needed	87150 80321 80359 80324 80361 80345 80362 80346 80365 80347 80367 80348 80368 80349 80369 80353 80372 80354 80373 80356 83992
80307	Drug Screen, Serum or Plasma	Positive	Confirmation by GC/MS of each component as needed	80358 80324 80358 80345 80359 80346 80361 80348 80365 80349 83992
80305	Drug Screen, Universal (Labor & Delivery ONLY)	Positive	Confirmation by GC/MS of each component as needed	80353 80154 83805 80184 83840 82145 83887 82520 83925 82542 83992
82175 82300 83655 (82525+ 83825 84630)	Heavy Metals Panel 4 (or 6), Urine	Positive Arsenic	Fractionated Arsenic, Urine	82175
83020 85025	Hemoglobin Electrophoresis	Unidentifiable abnormal band present	Referral lab tests as determined by pathologist	Varies
0.50.40	H D.G. O	S band present	Sickle Cell Screen	85660
87340 87624	Hepatitis B Surface Antigen HPV High Risk by TMA with Reflex to Genotypes	Reactive Positive	HBsAg Confirmation HPV Genotypes 16 and 18/45	87341 87625
87389	Human Immunodeficiency Virus (HIV) 1 & 2 Antibodies	Reactive	HIV 1 & 2 Antibody Differentiation, Supplemental	86701 + 86702
86790	Human T-Lymphotropic Virus (HTLV) Types I/II Antibodies	Positive	HTLV I/II Confirmation by Western Blot	86689
80061 83605	Lipid Panel (Outpatient Only) Lactate-Initial	Triglyceride >400 mg/dL >2.0 mmol/L	Direct LDL 1st Lactate repeat, if still >2.0 mmol/l a 2nd Lactate repeat is performed	83721 83605

CPT	INITIAL TEST	REFLEX CRITERIA	REFLEX TEST	CPT
	Lupus Anticoagulant (LA)	Abnormal	Workup may include one or more:	CII
85730	• PTT-LA	Tionomai	Phase LA Hexagonal delta	85598
85612	• dRVV Screen		dRVV Confirm	85613
03012	are v v sereen		DVVT 50:50 Mix	85613
			DVVI 30.30 IVIIX	05015
86618	Lyme Antibodies, Total with Reflex to IgG and IgM	Positive	Borrelia burgdorferi Ab, IgG by Immunoblot	86617
	Immunoblot, Early Disease		Borrelia burgdorferi Ab, IgM by Immunoblot	86617
86618	Lyme Antibodies, Total with Reflex to IgG Immunoblot, Late Disease	Positive	Borrelia burgdorferi Ab, IgG by Immunoblot	86617
82664	Protein Electrophoresis, Serum	Gamma Peak ≤0.5 g/dL	IgG, IgA, IgM	82784 x3
		Paraprotein present	IgG, IgA, IgM, and Immunofix if new patient not previously identified	82784 x5 86334
84166	Protein Electrophoresis, Urine	Paraprotein present	Immunofix if new patient not previously identified	86335
87430	Rapid Strep Group A Antigen	Negative	Strep Group A DNA	87651
	Rh Immunoglobulin Workup:		Upper Respiratory Culture	87070
85461	Fetal Cell Screen	Positive	Kleihauer-Betke Stain	85460
86800	Thyroglobulin	Above the normal reference limit	Thyroglobulin by LC-MS/MS	84432
		Negative	Thyroglobulin by CIA	84432
83516	Tissue Transglutaminase Antibody, IgA	≥4 U/mL	Endomysial Antibody, IgA titer by IFA	86256
86780	Treponema Antibody	Positive or Equivocal	RPR	86593
			If RPR non-reactive, then TP-PA (T. pallidum Particle Agglutination)	86780
84443	TSH with Reflex to Free T4	TSH > or < normal range for patient's age	Free T4	84439
	Type and Screen:	Antibody Screen	Workup may include any/all:	
86900	ABO Group	Positive	Antibody Identification Panel	86870
86901	Rh Type		Direct Antiglobulin Test for	86880 x3
86850	Antibody Screen		AHG, IgG, C3d	
			Antigen Type patient RBCs	86905
			(one antigen type per antibody ID'd)	
			Antibody Elution	86860
			Antibody Titer (pregnant patient, antibody is associated to HDFN)	86886
			Hoxworth Reference Case	86999
			If inpatient: • Antigen Type donor RBCs	86902
			(one antigen type per antibody ID'd per unit)	96022

Appearance not clear

Blood, Leukocyte

Esterase or Nitrite

Positive Leukocyte

WBC ≥6-10/hpf

Esterase or Nitrite, or

and/or positive Protein,

• Crossmatch pRBCs (per unit)

Urinalysis with Microscopic

Urine Culture

86922

81003

with

81001

87086

Replace

Microscopic

Culture

Urinalysis with Reflex to

Urinalysis with Reflex to

81003

81001

Page 4 of 4 Reflex Testing

CPT	INITIAL TEST	REFLEX CRITERIA	REFLEX TEST	CPT
85240	vWD Complete	One or more:	von Willebrand Multimer Analysis	85247
85246	Profile	VW Activity/VW		
85245		Antigen ratio < 0.7		
		Factor 8 Activity <50%		
		von Willebrand Antigen, vWF: AG <50%		
		von Willebrand Activity, vWF, R:Co <50%		
86022	Heparin-Induced Platelet Antibody w/reflex to Serotonin	Positive	Serotonin Release Assay	86022
	Release Assay			

(Blue: PLP / Gray: ARUP/ Green: Cincinnati Children's)

REFERENCE

HHS Office of Inspector General. Publication of OIG Compliance Program for Clinical Laboratories. *Federal Register* Notice, Vol. 63, No. 163, August 24, 1998, 45076-45087.